CLINICAL TRIALS PROFILE FOR PROVENTIL-HFA
✉ Email this page to a colleague
All Clinical Trials for PROVENTIL-HFA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00521222 ↗ | Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes | Unknown status | Columbia University | N/A | 2007-06-01 | The investigators are conducting a study of asthma patients who use fluticasone with salmeterol (Advair) or any other combination of an inhaled corticosteroid (ICS) and a long acting beta agonist (LABA) to manage their asthma symptoms. Participants begin the study by continuing to use fluticasone with salmeterol or substituting fluticasone with salmeterol for their current ICS/LABA medication at their regular dose or the comparable dose(all study medications are provided) for a six-week period. Patients are then separated into 2 groups: one group is asked to use fluticasone (Flovent), the other to use fluticasone with salmeterol , twice daily over a 16-week period (patients will need to be seen monthly during this time). Neither study personnel nor patients will know which drug is being used. Patients are also asked to use a peak flow meter and record their daily results on a form, along with the number of puffs they use of their rescue inhaler each day. They also record any changes in asthma medications and information on any asthma episodes. The investigators hypothesize that there are certain patients with asthma who will do better when a long acting beta agonist is removed from their maintenance asthma medications. |
| NCT00550550 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) | Completed | ALK-Abelló A/S | Phase 3 | 2007-11-01 | The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma. |
| NCT00550550 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-11-01 | The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma. |
| NCT00562159 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) | Completed | ALK-Abelló A/S | Phase 3 | 2007-11-01 | This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet. |
| NCT00562159 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-11-01 | This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PROVENTIL-HFA
Condition Name
Clinical Trial Locations for PROVENTIL-HFA
Trials by Country
Clinical Trial Progress for PROVENTIL-HFA
Clinical Trial Phase
Clinical Trial Sponsors for PROVENTIL-HFA
Sponsor Name
